111-19-3Relevant academic research and scientific papers
Synthesis, Characterization, and Viscosification of Amidosulfobutaine and Zwitterionic Gemini Surfactants
Mansha, Muhammad,Ullah, Nisar,Kalgaonkar, Rajendra A.,Baqader, Nour
, p. 697 - 706 (2021)
The viscoelastic surfactants (VES)-based acid diverters are frequently used to divert acid flow from high-permeability layers into low-permeability for enhanced overall productivity of the treated well. In general, an optimum VES-based system possesses advantages of decrease in absorption loss, damage of reservoir, and improved adaptability of active agents to high salinity. Herein, we report the synthesis of three new zwitterionic gemini surfactants (1–3) and previously known amidosulfobutaine (C18AMP3SB) has been accomplished for the investigation of diverting acid performance. The synthesis of these surfactants was achieved by the amidation of the acid chlorides of commercially available fatty acids with 3-(dimethylamino)-1-propylamine followed by subsequent reactions with appropriate sultone or ethyl 4-bromobutanoate. The synthesized surfactants were well characterized by spectroscopic methods including IR and NMR spectroscopy. The thermogravimetric analysis (TGA) results suggested that surfactants (1–3) and C18AMP3SB possess excellent thermal stability, with no appreciable loss of mass up to 300°C. The viscosity measurements of the neat surfactants (1–3) and C18AMP3SB were performed under various temperatures, in the presence of different concentration of calcium chloride salt with the aid shear viscosimetry. The analysis revealed that the viscosity of neat C18AMP3SB increases with increase in concentration of CaCl2. With 10% CaCl2 solution, the viscosity was increased from 7.5 to 33.55 cPs, whereas in 20% CaCl2 the viscosity reached to 102 cPs with rise in temperature from ambient to 90°C. Moreover, the viscosity of neat surfactants (1–3) did not exhibit any appreciable viscosity change under the experimental conditions. However, the mixture of surfactants (1–3) each in combination with C18AMP3SB (1:1) displayed significant upsurge in the viscosity, up to more than 10 folds.
Electrochemical and nonelectrochemical analyses of cardo polyesters at the metal/0.5?M H2SO4 interface for corrosion protection
Unnisa, Chan Basha Nusrath,Chitra, Subramanian,Nirmala Devi, Gowraraju,Kiruthika, Ayyasamy,Roopan, Selvaraj Mohana,Hemapriya, Venkatesan,Chung, Ill-Min,Kim, Seung-Hyun,Prabakaran, Mayakrishnan
, p. 5425 - 5449 (2019)
With the aim of decreasing the corrosion of metal specimens, two polyesters, namely 4-(1-(4-methoxyphenyl)cyclohexyl)phenyl 3-oxobutanoate (MPOB) and 4-(1-(4-methoxyphenyl)cyclohexyl)phenyl 10-oxoundecanoate (MPOU), were synthesized and utilized as corrosion inhibitors. The synthesized polyesters were characterized by Fourier-transform infrared (FT-IR) and nuclear magnetic resonance spectral analyses, followed by thermogravimetric and differential scanning calorimetry analyses. The protective effect of the polyesters on mild-steel specimens in 0.5?M H2SO4 medium was evaluated by nonelectrochemical and electrochemical methods. Gravimetric measurements revealed a decreased corrosion rate with increasing concentration of the inhibitors, reaching a maximum inhibition efficiency of 79.88% for MPOB and 92.98% for MPOU at 1000?ppm concentration at room temperature. The obtained experimental data were best fit by the Langmuir adsorption isotherm, suggesting monolayer adsorption. Thermodynamic parameters supported a physisorption mechanism. Electrochemical impedance spectroscopy showed increased charge-transfer resistance (Rct), in turn decreasing the double-layer capacitance and thereby favoring good inhibition of corrosion of mild steel. Mixed-type inhibition was revealed by potentiodynamic polarization analysis, suppressing anodic metal dissolution and cathodic hydrogen evolution. The mode of adsorption of the inhibitors on the mild-steel surface was additionally evaluated by morphological study using FT-IR and atomic force microscopy (AFM) analyses.
Synthesis and characterization of cyclic alkyl tetraynes
Spantulescu, Andreea,Luu, Thanh,Yuming, Zhao,McDonald, Robert,Tykwinski, Rik R.
, p. 609 - 612 (2008)
Cyclic (4a-e) and linear (10) tetraynes have been studied. Macrocycles 4a-e are unstable to isolation as neat compounds, but 4b-e have been characterized in solution. 13C NMR spectroscopy shows a consistent downfield shift of the acetylenic resonances of 4c-e as ring strain increases. UV-vis spectroscopy demonstrates that ring strain has little effect on the HOMO-LUMO gap. X-ray crystallography of tetrabromoolefin 6b confirms the monomeric constitution of the precursors.
Synthesis and bio-evaluation of Tc-99 m-labeled fatty acid derivatives for myocardial metabolism imaging
Liu, Jianping,Xue, Qianqian,Wang, Huan,Wang, Hang,Wang, Dawei,Fang, Yu,Zhang, Huabei
, p. 596 - 604 (2016)
11C, 18F and 123I fatty acids are used for myocardial imaging, and 99mTc-labeled fatty acids are more desirable substitutes than other radiolabeled fatty acids. In the work reported, [99mTc]-CpTT-10-oxo-FPA (1c), [99mTc]-CpTT-12-oxo-FPA (2c), [99mTc]-CpTT-14-oxo-FPA (3c) and [99mTc]-CpTT-16-oxo-FPA (4c) were prepared with 60.76–70.92% of radiochemical yield and purity of more than 95%. These radiotracers (1c, 2c, 3c, 4c) were chemically stable when incubated in Sprague Dawley rat serum for 3 h at 37 °C. Tissue distribution studies in female mice indicated that 2c had high initial heart uptake (8.84%ID g?1 at 1 min post-injection) and 4c had long retention in the heart (1.45%ID g?1 at 30 min post-injection). Metabolite analysis showed 4c could be metabolized to 5c via β-oxidation with loss of two ?CH2? in the myocardium, the radiometabolite being excreted via urine. However, low heart uptake suggested that 4c cannot be used as a diagnostic imaging agent. Copyright
Synthesis of α,ω-Diketodiesters from Betulin
Ishmuratov, G. Yu.,Sayakhov, R. R.,Talipov, R. F.,Vydrina, V. A.,Yakovleva, M. P.,Zileeva, Z. R.
, p. 706 - 711 (2021/07/31)
A new synthesis of 3-oxo-28-hydroxylup-20(29)-ene from the available natural triterpenoid betulin was developed. α,ω-Diketodiesters were prepared for the first time by different methods from 3-oxo-28-hydroxylup-20(29)-ene and a series of natural dicarboxylic acids. Steglich reaction conditions gave the highest yields. One of the synthesized α,ω-diketodiesters was moderately active in vitro against A-549 lung carcinoma.
LIPID PRODRUGS OF GLUCOCORTICOIDS AND USES THEREOF
-
Paragraph 00404; 00405, (2020/09/12)
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF
-
Paragraph 00293, (2020/02/23)
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF
-
Paragraph 00411-00412, (2020/09/12)
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
LIPID PRODRUGS OF BTK INHIBITORS AND USES THEREOF
-
Paragraph 00405; 00420; 00421, (2020/09/12)
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS
-
Paragraph 00427; 00428, (2019/03/17)
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.
